Entering text into the input field will update the search result below

Millendo launches early-stage study of lead drug

  • Millendo Therapeutics (NASDAQ:MLND) announces dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301.
  • The first-in-human trial is designed to evaluate the safety and tolerability of MLE-301.
  • MLE-301 is a reversible antagonist of the human neurokinin 3 receptor or NK3R in development for the treatment of vasomotor symptoms associated with menopause.
  • “We are pleased to advance MLE-301 into clinical development, prioritizing our resources on this valuable asset and leveraging Millendo’s expertise in the NK3R category," said Julia C. Owens, President and CEO.
  • Press Release

Recommended For You

More Trending News

About TPST Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TPST--
Tempest Therapeutics, Inc.